Adding to the recent posts...
The likelihood of Rem-L to be approved for Covid-19 ARDS is significant:
- RCT - trial design agreed with NIH & FDA
- NIH funded - they have a big voice and part of PHEMCE
- Pandemic = increased political & economic pressure to approve
- Safety - demonstrated via various trials and also via JCR Temcell 4 years on the market already
- Low bar - if Gilead's product was approved based on little proven benefits, then Rem-L doesn't need overwhelming efficacy -good efficacy is enough
... now if we retail SHs can see this, what will the institutional investors see?
At what point will institutional investors see value here?
To me the last few weeks since 05/10/2020 the SP has bottomed - the turnaround is coming
Hang in there MSB'ers - HODL
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-362
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.010(0.84%) |
Mkt cap ! $1.370B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.18 | $1.312M | 1.103M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 22236 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 240969 | 31 |
View Market Depth
| Last trade - 10.50am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |